Influence of food on the absorption of albuterol Repetabs. 1989

A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
Department of Pharmacy, University of California, San Francisco 94143-0622.

A study was conducted in 12 healthy, nonsmoking male volunteers to examine the effect of food intake on the absorption profile of albuterol repeat-action tablets. This randomized crossover study consisted of two phases separated by a 1-week washout period. All subjects fasted 10 hours preceding drug administration. Each subject received two 4 mg albuterol repeat-action tablets with and without a high fat content breakfast. Plasma albuterol concentrations were determined by a gas chromatographic/mass spectrophotometric assay. Relative bioavailability was assessed by comparing areas under the plasma-albuterol concentration time curves as well as peak concentrations and time to peak concentration. No significant differences were noted between the two treatment phases in the area under the curve or peak plasma concentrations. The areas under the curve were 100 and 105 hr.ng/ml when the drug was administered with and without food, respectively. The corresponding peak plasma concentration values were 9.4 and 10.4 ng/ml, respectively. The only significant difference observed was in the maximum time to reach peak plasma concentrations, which was delayed by about 1 hour when the drug was administered with food. Therefore, food has minimal effect on the absorption of albuterol from repeat-action tablets.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
June 1991, Journal of clinical pharmacology,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
January 1992, The Journal of asthma : official journal of the Association for the Care of Asthma,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
January 1986, Journal of clinical pharmacology,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
December 1975, Lancet (London, England),
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
February 1992, Journal of clinical pharmacology,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
April 1987, Journal of clinical pharmacology,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
January 1982, The Journal of antimicrobial chemotherapy,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
January 1988, International journal of clinical pharmacology research,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
May 1979, European journal of clinical pharmacology,
A M Bolinger, and K Y Young, and J G Gambertoglio, and C J Newth, and G Zureikat, and M Powell, and P Leung, and M B Affrime, and S Symchowicz, and J E Patrick
July 1993, The Medical clinics of North America,
Copied contents to your clipboard!